Skip to contentA
Abbott Laboratories
A
ABTAbbott Laboratories Q1 2026 · 10-Q
Revenue$11.16B$11.16B+7.8% vs Q1 2025 Net Income$1.08B$1.08B−18.7% vs Q1 2025 EPS Diluted$0.61$0.61−19.7% vs Q1 2025 Operating Income$1,345,000,000−20.6% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Abbott Laboratories · CIK 1800 · Engraved from SEC EDGAR
Free Cash Flowderived$916,000,000−1.8% Margins · derivedOperating margin12.0%−4.3 pt vs Q1 2025
Net margin9.6%−3.1 pt vs Q1 2025
ended Mar 31, 2026 · filed Apr 29, 2026 · 29 d after period end